Gamgertamig (OM336)
BCMAxCD3
AICSAIAIBD
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of potential best-in-class therapies.
We are advancing a pipeline of T-cell engagers, anchored by gamgertamig, a potential first and best-in-class BCMAxCD3 T-cell engager for autoimmune indications. Gamgertamig is being developed in collaboration with Gilead. Gilead also has the right to opt-into a 50/50 profit share on the preclinical T-cell engager programs after clinical proof of concept.
AICSAIAIBD
Undisclosed
Note: AIBD, autoimmune bullous diseases; AIC, autoimmune cytopenia; AIHA, autoimmune hemolytic anemia; APS, antiphospholipid syndrome; BCMA, B-cell maturation antigen; CD3: cluster of differentiation 3; SAI, seropositive autoimmune diseases; CTA, clinical trial application; IIM, Idiopathic inflammatory myopathy; myositis, dermatomyositis, polymyositis, immune mediated necrotizing myopathy, anti-synthetase syndrome; IND, investigational new drug; ITP, immune thrombocytopenia; PF, pemphigus foliaceus; PV, pemphigus vulgaris; SjD, Sjogren’s disease; TCE, T-cell engager
GLPG3667 is an investigational TYK2 (Tyrosine Kinase 2) inhibitor designed to selectively modulate immune pathways involved in inflammatory and autoimmune diseases. As part of its ongoing efforts to maximize the value of the program for both patients and the Company, Lakefront is evaluating all strategic options.
DMSLE
SLE: Systemic lupus erythematosus; DM: Dermatomyositis
At Lakefront Biotherapeutics, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative medicines.